IRD earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -2.33. Updated 2026-07-23.
Opus Genetics (IRD) Research Hub
Opus Genetics (IRD) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 6.04 USD (+5.41%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.33, market cap 0.25B. This hub links to the full technical, earnings and options research available for IRD.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.04 USD (+5.41%) |
| 52-week range | 2.82 USD – 7.07 USD |
| Trend regime | Range |
| 14-day RSI | 77.2 (Overbought) |
| Trailing P/E | -2.33 |
| Market cap | 0.25B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for IRD
Covered Call on IRD: how it works, illustrative setup around the real 6.04 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on IRD: how it works, illustrative setup around the real 6.04 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on IRD: how it works, illustrative setup around the real 6.04 USD price, max profit/loss, breakeven and when to use it. Educational.
IRD technical analysis: range, last 6.04 USD, RSI 77.2, 52w range 2.82 USD–7.07 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is IRD in?
Opus Genetics (IRD) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is IRD in an uptrend or downtrend?
As of 2026-09-11, IRD is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is IRD's trailing P/E ratio?
IRD's trailing P/E is -2.33, with a market cap of 0.25B. See the earnings research page for full valuation detail.
When does IRD next report earnings?
IRD is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.15 USD.